Belite Bio to Present Phase 3 Stargardt Disease Data at APAO Congress
Event summary
- Belite Bio will present topline Phase 3 DRAGON study results for tinlarebant in Stargardt disease at the APAO Congress on February 6, 2026.
- The presentation will include individual patient case reports from the Phase 3 trial.
- Belite Bio will host a sponsored lunch symposium and maintain an exhibition booth during the event.
- Tinlarebant is an oral therapy targeting vitamin A-based toxins in degenerative retinal diseases.
The big picture
Belite Bio's presentation at the APAO Congress comes at a critical juncture for tinlarebant, its lead candidate for Stargardt disease, a condition with no approved treatments. The Phase 3 DRAGON study results could position the company as a leader in addressing this unmet medical need, potentially attracting partnerships or acquisition interest. The broader ophthalmology sector is watching closely, as successful outcomes could validate the approach of targeting vitamin A-based toxins in degenerative retinal diseases.
What we're watching
- Regulatory Pathway
- Whether the Phase 3 DRAGON study results will support accelerated regulatory approval for tinlarebant in Stargardt disease.
- Market Potential
- The pace at which Belite Bio can commercialize tinlarebant if approved, given the lack of current FDA-approved treatments for Stargardt disease.
- Clinical Validation
- How individual patient case reports from the Phase 3 trial may influence broader adoption or skepticism among medical professionals.
Related topics